Despite billion-dollar pandemic boost, AbCellera still seeks ‘escape velocity’ By Aleksandra Sagan and David Reevely
How AI gave Canada an early lead in finding new medicines—and how we could lose it By David Reevely and Aleksandra Sagan
B.C.’s AbCellera pushing feds, province for ‘patent-box’ tax breaks for IP-heavy companies By Aleksandra Sagan
As AbCellera plans massive expansion ‘for decades to come,’ Vancouver braces for impact By Aleksandra Sagan
It’s raining unicorns: What’s behind the sudden surge in B.C.-based billion-dollar companies? By Aleksandra Sagan
‘It is very personal’: AbCellera’s COVID-19 treatment is saving lives in the U.S. In Canada, it’s sitting in storage. Now the company’s CEO is speaking out By Aleksandra Sagan
